Ann: Trading Halt, page-43

With everything going wrong at the moment (and the residual sentiment from acne results) it's easy to feel nervous about this announcement. However, we have to remember that COVID-19 (fortunately) has had no impact on this trial. If the company is being transparanet with the market, then we should not expect similar issues as 1503. We know from phase 1 trials that this drug performed in line with leading competitors after 4 weeks and it is expected to perform even better after 12. There's no crystal ball but I'm confident this is going to be a good result. Only question is whether the SP will react and if it was worth the risk of holding through this period given we can expect much lower returns if announcement is positive.